pulmonari
infect
critic
ill
patient
common
associ
high
morbid
mortal
piperacillintazobactam
frequent
use
therapi
critic
ill
patient
pulmonari
infect
antibiot
concentr
lung
reflect
target
site
antibiot
concentr
patient
pneumonia
aim
studi
assess
plasma
intrapulmonari
pharmacokinet
pk
piperacillintazobactam
critic
ill
patient
administ
standard
piperacillintazobactam
regimen
popul
pk
model
develop
describ
plasma
intrapulmonari
piperacillin
tazobactam
concentr
probabl
piperacillin
exposur
reach
pharmacodynam
endpoint
impact
pulmonari
permeabl
piperacillin
tazobactam
pulmonari
penetr
explor
median
piperacillin
tazobactam
pulmonari
penetr
ratio
respect
pulmonari
piperacillin
tazobactam
concentr
unpredict
neg
correl
pulmonari
permeabl
current
piperacillintazobactam
regimen
may
insuffici
treat
pneumonia
caus
piperacillintazobactam
suscept
organ
critic
ill
patient
pulmonari
infect
critic
ill
patient
result
unaccept
high
mortal
morbid
increas
length
hospit
stay
associ
healthcar
cost
approxim
patient
admit
intens
care
unit
icu
present
pulmonari
infect
addit
lung
primari
site
infect
nosocomi
infect
occur
within
icu
attribut
mortal
ventilatorassoci
pneumonia
estim
may
high
certain
subgroup
pulmonari
infect
critic
ill
patient
caus
wide
rang
organ
includ
difficulttotreat
organ
pseudomona
aeruginosa
use
appropri
target
antimicrobi
chemotherapi
associ
improv
clinic
outcom
howev
clinic
outcom
patient
infect
suscept
organ
receiv
appropri
antimicrobi
agent
remain
suboptim
partli
due
mark
pharmacokinet
pk
variabl
occur
critic
ill
patient
pk
critic
ill
patient
may
affect
physiolog
chang
associ
ill
typic
result
higher
proport
patient
receiv
suboptim
drug
exposur
fix
regimen
use
addit
mani
current
licens
drug
regimen
inform
studi
perform
noncrit
ill
patient
may
necessarili
appropri
outsid
context
piperacillintazobactam
combin
extendedspectrum
antibiot
piperacillin
inhibitor
tazobactam
piperacillintazobactam
broadspectrum
action
includ
gramposit
gramneg
anaerob
bacteria
consequ
piperacillintazobactam
common
choic
direct
empir
treatment
critic
ill
patient
pharmacodynam
index
best
link
piperacillin
concentr
antimicrobi
effect
fraction
dose
interv
unbound
piperacillin
concentr
minimum
inhibitori
concentr
mic
nearmaxim
antimicrobi
effect
gener
observ
free
piperacillin
concentr
exceed
mic
least
dose
interv
ft
mic
howev
ft
mic
may
appropri
critic
ill
patient
global
increas
incid
antimicrobi
resist
focus
attent
antimicrobi
drug
regimen
safe
effect
also
minimis
probabl
emerg
antimicrobi
resist
recent
use
hollow
fibr
infect
model
piperacillintazobactam
versu
pseudomona
aeruginosa
demonstr
trough
cmin
total
piperacillin
concentrationtom
ratio
prevent
emerg
antimicrobi
resist
identif
piperacillintazobactam
regimen
enabl
attain
pharmacodynam
target
efficaci
suppress
emerg
antimicrobi
resist
may
led
improv
clinic
outcom
increas
clinic
longev
commonli
use
agent
adequ
antibiot
concentr
site
infect
requir
effect
antimicrobi
activ
pulmonari
infect
epitheli
line
fluid
elf
repres
compart
clinic
relev
access
measur
drug
concentr
gener
clinic
exposurerespons
relationship
within
elf
poorli
defin
understand
drug
penetr
elf
drug
exposurerespons
relationship
within
compart
import
consider
bridg
preclin
clinic
studi
pulmonari
penetr
ratio
partit
coeffici
relat
drug
exposur
elf
drug
exposur
plasma
healthi
volunt
data
suggest
area
concentr
auc
time
curv
elf
plasma
piperacillin
tazobactam
auc
respect
gener
pauciti
inform
regard
elf
penetr
antimicrobi
agent
critic
ill
patient
two
studi
suggest
piperacillin
tazobactam
elf
concentr
respect
pair
plasma
concentr
primari
aim
clinic
studi
quantifi
pulmonari
penetr
piperacillin
tazobactam
critic
ill
patient
also
investig
factor
may
influenc
penetr
drug
lung
popul
pharmacokinet
model
use
describ
observ
plasma
elf
concentr
piperacillin
tazobactam
critic
ill
patient
mont
carlo
simul
use
explor
impact
pharmacokinet
variabl
plasma
elf
piperacillin
exposur
achiev
desir
pharmacodynam
target
addit
influenc
pulmonari
permeabl
pulmonari
piperacillin
tazobactam
concentr
investig
june
juli
eighteen
critic
ill
patient
enrol
mean
age
year
mean
apach
ii
score
tabl
one
patient
infect
novel
coronaviru
exclud
analys
issu
relat
biosafeti
firstdos
pharmacokinet
assess
four
patient
steadi
state
pharmacokinet
assess
seventeen
patient
receiv
mean
dose
rang
four
patient
renal
replac
therapi
receiv
piperacillintazobactam
everi
hour
remain
patient
receiv
piperacillintazobactam
everi
hour
five
patient
receiv
piperacillintazobactam
minut
remain
patient
receiv
piperacillintazobactam
minut
total
plasma
elf
sampl
obtain
pharmacokinet
analys
three
piperacillin
plasma
sampl
piperacillin
elf
sampl
tazobactam
plasma
sampl
limit
assay
quantif
three
nondirect
bronchial
lavag
nbl
specimen
two
singl
patient
collect
clinic
requir
high
fraction
inspir
oxygen
fio
preclud
sampl
singl
patient
drop
oxygen
satur
requir
temporari
increas
fio
chang
oxygen
satur
observ
patient
chang
respiratori
cardiovascular
paramet
observ
four
hour
follow
collect
nbl
sampl
fit
mathemat
model
observ
data
accept
linear
regress
predictedversusobserv
plasma
piperacillin
tazobactam
concentr
reveal
follow
relationship
observ
piperacillin
concentr
predict
piperacillin
concentr
r
similarli
observ
tazobactam
concentr
predict
tazobactam
concentr
r
linear
regress
predict
observ
piperacillin
tazobactam
concentr
elf
given
observ
piperacillin
concentr
predict
piperacillin
concentr
r
observ
tazobactam
concentr
predict
tazobactam
concentr
r
plasma
piperacillin
tazobactam
concentr
mean
weight
bia
respect
biasadjust
mean
weight
precis
respect
piperacillin
tazobactam
concentr
elf
mean
weight
bia
biasadjust
mean
weight
precis
respect
paramet
estim
popul
analysi
summar
tabl
intercompartment
piperacillin
clearanc
central
peripher
central
elf
compart
lhour
respect
intercompartment
tazobactam
clearanc
central
peripher
central
elf
compart
lhour
lhour
respect
volum
peripher
compart
l
l
piperacillin
tazobactam
respect
plot
observ
piperacillin
tazobactam
concentr
previous
publish
studi
overlaid
predict
th
th
th
th
th
centil
drug
concentr
studi
simul
use
popul
pharmacokinet
model
reveal
high
degre
concord
figur
simul
concentrationtim
profil
show
median
th
th
th
th
centil
drug
concentr
plasma
elf
follow
administr
five
simul
dose
piperacillin
gram
tazobactam
gram
minut
infus
everi
eight
hour
shown
figur
median
auc
elf
auc
unbound
plasma
penetr
ratio
rang
piperacillin
rang
tazobactam
simul
plasma
elf
exposur
individu
patient
use
bayesian
posterior
paramet
estim
allow
assess
drug
penetr
plasma
elf
interrelationship
two
coadminist
drug
statist
signific
correl
elf
piperacillin
exposur
auc
elf
unbound
plasma
piperacillin
exposur
auc
unbound
plasma
figur
similarli
statist
signific
correl
elf
tazobactam
exposur
auc
elf
unbound
plasma
tazobactam
exposur
auc
unbound
plasma
figur
unbound
tazobactam
exposur
plasma
critic
ill
patient
statist
significantli
posit
correl
unbound
piperacillin
plasma
exposur
auc
unbound
plasma
p
figur
also
statist
signific
posit
correl
tazobactam
piperacillin
elf
exposur
auc
elf
figur
mean
pulmonari
permeabl
estim
ratio
ureacorrect
total
protein
elf
plasma
total
protein
concentr
median
sd
felton
et
al
clin
pharmacol
ther
author
manuscript
avail
pmc
octob
statist
signific
neg
correl
observ
piperacillin
penetr
ratio
auc
elf
auc
unbound
plasma
pulmonari
permeabl
figur
contrast
statist
signific
correl
seen
tazobactam
penetr
ratio
auc
elf
auc
unbound
plasma
pulmonari
permeabl
r
figur
mont
carlo
simul
use
estim
probabl
achiev
predefin
pharmacodynam
target
result
probabl
target
attain
analysi
piperacillin
shown
figur
administr
piperacillin
three
time
daili
minut
infus
treat
organ
mic
mgl
result
patient
achiev
pharmacodynam
target
ft
mic
ft
mic
cminmic
respect
treatment
organ
mic
mgl
ie
current
clsi
eucast
breakpoint
pseudomona
auriginosa
result
patient
achiev
pharmacodynam
target
ft
mic
ft
mic
cminmic
respect
predict
target
attain
plasma
elf
mic
similar
exampl
target
attain
rate
use
endpoint
unbound
piperacillin
concentr
ft
mic
mic
mgl
respect
comparison
use
pharmacodynam
target
elf
ie
mic
result
target
attain
rate
mic
mgl
respect
suscept
organ
ie
mic
rang
mgl
unbound
plasma
elf
concentr
mic
dose
interv
simul
patient
frequenc
distribut
piperacillintazobactam
suscept
isol
caus
hospitalacquir
ventilatorassoci
pneumonia
overal
respons
rate
critic
ill
patient
vap
estim
figur
piperacillin
administ
empir
ie
mic
known
critic
ill
patient
vap
would
achiev
plasma
ft
mic
patient
would
achiev
elf
mic
contrast
piperacillin
administ
critic
ill
patient
vap
caus
suscept
organ
ie
mic
mgl
patient
would
achiev
plasma
ft
mic
patient
would
achiev
elf
mic
suppress
emerg
antimicrobi
resist
follow
empir
administr
piperacillin
critic
ill
patient
vap
would
achiev
plasma
cminmic
patient
would
achiev
elf
cminmic
piperacillin
administ
critic
ill
patient
vap
caus
suscept
organ
patient
would
achiev
plasma
cmin
mic
patient
would
achiev
elf
cminmic
inspect
concentrationtim
profil
piperacillin
tazobactam
illustr
mark
pharmacokinet
variabl
critic
ill
patient
figur
pharmacokinet
variabl
notabl
evid
lung
compar
plasma
compound
estim
clearanc
volum
central
compart
popul
pk
valid
generaliz
result
suggest
concord
simul
concentr
popul
pk
model
data
previous
publish
group
critic
ill
patient
see
figur
betalactam
antibiot
penetr
lung
passiv
diffus
diffus
tissu
depend
concentr
gradient
across
biolog
membran
surfac
area
membran
diffus
coeffic
diffus
coeffici
princip
influenc
physicochem
characterist
drug
eg
degre
lipophil
extent
protein
bind
posit
correl
plasma
elf
exposur
piperacillin
tazobactam
howev
relationship
reach
statist
signific
unexpect
perhap
due
modest
number
patient
studi
studi
use
ratio
total
protein
elf
plasma
surrog
measur
lung
permeabl
expect
see
increas
diffus
drug
increas
pulmonari
protein
penetr
howev
observ
statist
signific
neg
correl
piperacillin
pulmonari
penetr
ratio
auc
elf
auc
unbound
plasma
pulmonari
permeabl
figur
pulmonari
permeabl
increas
reduct
rel
proport
piperacillin
penetr
lung
tazobactam
statist
signific
correl
pulmonari
penetr
ratio
auc
elf
auc
unbound
plasma
pulmonari
permeabl
relationship
pulmonari
permeabl
pulmonari
drug
concentr
previous
investig
antibiot
pulmonari
vancomycin
penetr
shown
higher
patient
increas
pulmonari
permeabl
measur
elf
albumin
concentr
lung
penetr
antibiot
shown
depend
plasma
albumin
concentr
increas
tissu
penetr
occur
higher
unbound
plasma
antibiot
concentr
observ
patient
hypoalbuminaemia
phenomenon
primarili
affect
highli
protein
bound
agent
ertapenem
flucloxacillin
number
potenti
explan
relationship
piperacillin
lung
penetr
permeabl
methodolog
small
studi
extrem
pk
variabl
observ
plasma
elf
drug
concentr
multipl
measur
pulmonari
sampl
concentr
dilut
factor
deriv
comparison
urea
concentr
plasma
pulmonari
sampl
may
contribut
greater
variabl
observ
pulmonari
drug
concentr
compar
plasma
concentr
possibl
biolog
explan
includ
dilut
intrapulmonari
piperacillin
due
larger
elf
volum
associ
increas
pulmonari
permeabl
altern
antibiot
substrat
organ
anion
transport
organ
kidney
disrupt
activ
transport
system
may
occur
injur
lung
critic
ill
patient
exhibit
increas
permeabl
protein
anoth
explan
may
increas
pulmonari
protein
permeabl
preferenti
affect
diffus
piperacillin
tazobactam
lung
therefor
lung
low
protein
permeabl
piperacillin
diffus
lung
faster
diffus
revers
occur
lung
higher
protein
permeabl
valid
neg
correl
pulmonari
piperacillin
penetr
pulmonari
permeabl
requir
similar
clinic
cohort
measur
antimicrobi
agent
elf
may
truli
reflect
drug
concentr
within
pulmonari
subcompart
microdialysi
techniqu
may
provid
better
estim
pulmonari
drug
concentr
bronchoalveolar
lavag
quantifi
drug
concentr
elf
howev
due
practic
difficulti
pulmonari
microdialysi
elf
sampl
remain
commonli
utilis
techniqu
preclin
clinic
studi
studi
use
nbl
nbl
safe
effect
way
sampl
lung
quantifi
antimicrobi
drug
concentr
elf
critic
ill
patient
nbl
less
invas
bronchoscopi
bronchoalveolar
lavag
bal
allow
multipl
nbl
sampl
collect
throughout
dose
interv
collect
two
nbl
sampl
patient
rather
one
bal
provid
robust
estim
concentrationtim
profil
elf
individu
patient
one
minor
advers
event
report
follow
nbl
antibiot
pharmacodynam
index
best
link
drug
exposur
antibacteri
effect
fraction
dose
interv
free
drug
concentr
mic
piperacillin
unbound
piperacillin
concentr
must
mic
least
dose
interv
gener
associ
near
maxim
efficaci
ft
mic
recent
demonstr
trough
unbound
piperacillin
concentr
mic
ratio
requir
suppress
emerg
antimicrobi
resist
cminmic
target
attain
analysi
figur
empir
administr
piperacillin
three
time
daili
minut
infus
ie
mic
known
result
probabl
attain
pharmacodynam
target
plasma
ft
mic
probabl
attain
pharmacodynam
target
elf
mic
probabl
achiev
pharmacodynam
target
increas
plasma
elf
respect
mic
known
organ
mic
beyond
breakpoint
ie
mgl
exclud
therefor
patient
suscept
organ
suboptim
drug
exposur
furthermor
approxim
patient
achiev
plasma
elf
pharmacodynam
target
associ
suppress
antimicrobi
resist
cminmic
analysi
identifi
two
import
issu
firstli
piperacillin
three
time
daili
minut
infus
inadequ
effect
treatment
suppress
emerg
antimicrobi
resist
unaccept
high
proport
critic
ill
patient
especi
pneumonia
result
infect
less
suscept
organ
secondli
probabl
achiev
pharmacodynam
target
ie
ft
mic
cminmic
etc
plasma
elf
similar
plasma
piperacillin
concentr
precis
predict
elf
piperacillin
concentr
consequ
individu
suffici
plasma
piperacillin
exposur
inadequ
elf
piperacillin
exposur
viceversa
elf
rather
plasma
exposur
shown
predict
outcom
antimicrobi
agent
caus
organ
isol
patient
make
explor
relationship
piperacillin
plasma
elf
pharmacokinet
pharmacodynam
ft
mic
cminmic
clinic
outcom
imposs
appropri
power
clinic
studi
requir
examin
whether
piperacillin
exposur
plasma
elf
better
predict
clinic
outcom
addit
tazobactam
piperacillin
extend
activ
produc
strain
organ
enterobacteriacea
staphylococcu
aureu
h
influenza
catarrhali
current
regimen
piperacillintazobactam
fix
ratio
support
invitro
studi
howev
pharmacodynam
index
best
link
inhibitor
exposur
effect
poorli
defin
fraction
dose
interv
inhibitor
concentr
threshold
threshold
ii
area
inhibitor
concentr
time
curv
suggest
relev
pharmacodynam
indec
requir
concentr
inhibitor
depend
amount
type
tazobactam
penetr
lung
critic
ill
patient
mark
variabl
therefor
subset
patient
may
insuffici
pulmonari
tazobactam
concentr
adequ
inhibit
caus
hydrolysi
piperacillin
clinic
failur
despit
adequ
piperacillin
exposur
increas
tazobactam
dosag
maintain
piperacillin
dosag
may
overcom
product
demonstr
invivo
mening
model
plasma
tazobactam
exposur
reflect
tazobactam
exposur
elf
identif
patient
poor
pulmonari
tazobactam
penetr
difficult
appear
requir
direct
sampl
lung
conclus
primari
aim
studi
develop
valid
mathemat
model
describ
piperacillin
tazobactam
concentr
plasma
lung
critic
ill
patient
addit
show
unexpect
relationship
increas
pulmonari
permeabl
associ
reduct
pulmonari
piperacillin
penetr
also
demonstr
predict
pulmonari
piperacillin
tazobactam
exposur
basi
plasma
drug
exposur
may
unreli
approprialti
power
clinic
trial
requir
defin
relationship
plasma
pulmonari
drug
exposur
establish
impact
pulmonari
rather
plasma
drug
exposur
clinic
outcom
addit
preclin
clinic
studi
requir
investig
mechan
lung
penetr
patient
pneumonia
biomark
relat
pulmonari
permeabl
drug
penetr
could
incorport
covari
mathemat
model
improv
predict
pulmonari
drug
exposur
new
regimen
piperacillintazobactam
may
requir
optimis
drug
concentr
lung
site
infect
like
singl
regimen
suitabl
individu
elf
exposur
shown
predict
clinic
outcom
great
accuraci
plasma
exposur
covari
pulmonari
drug
penetr
identifi
direct
measur
drug
concentr
pulmonari
compart
adjust
individu
regimen
may
requir
south
manchest
nh
trust
manchest
uk
elig
inclus
piperacillintazobactam
stragen
uk
administ
less
minut
everi
eight
hour
except
patient
creatinin
clearanc
renal
replac
therapi
administ
drug
everi
hour
written
inform
consent
obtain
next
kin
patient
particip
studi
addit
retrospect
inform
consent
obtain
patient
surviv
regain
capac
give
consent
demograph
data
includ
age
sex
race
height
weight
diseas
sever
apach
ii
sofa
score
underli
renal
function
presenc
renal
replac
therapi
clinic
outcom
record
sampl
perform
follow
administr
first
dose
piperacillintazobactam
possibl
patient
underw
sampl
steadyst
mean
halflif
piperacillin
hr
patient
assum
steadyst
second
dose
previous
publish
optim
design
sampl
schedul
use
inform
time
collect
plasma
sampl
plasma
sampl
collect
hour
initi
infus
first
dose
immedi
prior
dose
hour
follow
initi
infus
steadi
state
plasma
sampl
collect
lithium
heparin
contain
tube
soon
collect
plasma
sampl
centrifug
x
g
minut
sampl
store
ml
aliquot
prior
analysi
nondirect
bronchial
lavag
nbl
assum
equival
bronchoalveolar
lavag
use
recoveri
intrapulmonari
sampl
two
intrapulmonari
sampl
collect
patient
steadyst
dose
interv
sampl
collect
hour
follow
initi
infus
patient
requir
inspir
oxygen
b
requir
posit
end
expiratori
pressur
c
endotrach
suction
lead
sever
prolong
desatur
sever
bronchospasm
e
uncontrol
persist
rais
intracrani
pressur
f
sever
dissemin
intravascular
coagul
nbl
sampl
collect
briefli
suitabl
patient
preoxygen
oxygen
minut
prior
sampl
suction
cathet
introduc
bronchia
tree
wedg
ml
steril
normal
salin
instil
second
immedi
aspir
typic
ml
normal
salin
recov
patient
monitor
four
hour
nbl
sign
cardiorespiratori
compromis
soon
collect
nbl
sampl
filter
filter
centrifug
x
g
minut
sampl
store
ml
aliquot
prior
analysi
blank
lavag
fluid
respect
standard
curv
made
stock
solut
mgl
piperacillin
tazobactam
respect
intern
standard
caffein
water
mgl
sigma
aldrich
dorset
uk
betweenday
coeffici
variat
piperacillin
tazobactam
lower
limit
detect
piperacillin
tazobactam
plasma
lavag
fluid
mgl
urea
concentr
plasma
lavag
fluid
perform
use
colorimetr
techniqu
quantichromtm
urea
assay
kit
gentaur
bvba
bioxi
belgium
standard
curv
urea
assay
linear
concentr
rang
mgdl
plasma
sampl
dilut
prior
measur
urea
drug
concentr
nbl
sampl
assum
reflect
elf
drug
concentr
correct
dilut
introduc
lavag
sampl
use
urea
dilut
method
urea
concentr
assum
plasma
elf
therefor
comparison
urea
concentr
plasma
lavag
fluid
allow
estim
dilut
caus
instil
lavag
fluid
lung
concentr
piperacillin
tazobactam
elf
estim
use
follow
formula
pulmonari
permeabl
assum
proport
ratio
mean
total
protein
concentr
plasma
elf
total
protein
quantifi
plasma
use
total
protein
assay
abbott
architect
abbott
laboratori
il
usa
colorimetr
assay
use
biuret
reagent
detect
presenc
peptid
bond
limit
detect
total
protein
gdl
limit
quantif
gdl
imprecis
total
protein
assay
total
coeffici
variat
protein
elf
quantifi
use
upro
assay
abbott
architect
abbott
laboratori
il
usa
assay
use
turbidimetr
procedur
benzethonium
chlorid
use
protein
denatur
agent
limit
quantif
detect
upro
assay
mgdl
imprecis
assay
total
coeffici
variat
elf
protein
concentr
correct
dilut
use
urea
dilut
method
describ
data
analyz
use
popul
pharmacokinet
methodolog
nonparametr
adapt
grid
npag
program
pmetric
piperacillin
tazobactam
threecompart
structur
mathemat
model
assum
appropri
popul
analysi
differenti
equat
threecompart
structur
mathemat
model
use
shown
x
x
x
amount
piperacillin
mg
central
peripher
elf
compart
respect
r
repres
infus
piperacillin
cl
lhr
clearanc
vc
volum
central
compart
l
k
cp
k
pc
k
celf
k
elfc
firstord
intercompartment
rate
constant
central
peripher
central
elf
compart
covari
includ
structur
model
elimin
movement
drug
central
compart
peripher
elf
compart
firstord
process
pharmacokinet
data
weight
invers
measur
assay
varianc
piperacillin
tazobactam
sampl
drug
concentr
limit
assay
quantif
exclud
analysi
polynomi
describ
assay
varianc
deriv
regress
measur
mean
drug
concentr
standard
deviat
sampl
known
high
low
piperacillin
tazobactam
concentr
mean
median
standard
deviat
popul
paramet
estim
bayesian
posterior
estim
paramet
also
obtain
patient
use
popul
one
util
npag
scatter
plot
observ
versu
predict
piperacillin
concentr
examin
popul
whole
individu
patient
fit
structur
model
data
assess
follow
way
loglikelihood
valu
b
coeffici
determin
r
slope
yintercept
regress
observedpredict
plot
bayesian
step
c
akaik
inform
criterion
aic
intercompartment
clearanc
volum
peripher
compart
estim
algebra
use
equat
q
intercompartment
clearanc
lhour
v
c
v
p
volum
central
periperpher
compart
respect
k
k
intercompartment
rate
constant
hr
simul
perform
adpat
observ
data
previou
pharmacokinet
studi
use
valid
dataset
studi
boselli
et
al
patient
administ
minut
intraven
load
dose
piperacillintazobactam
g
follow
daili
continu
infus
either
g
g
three
plasma
sampl
least
hour
apart
one
nbl
sampl
collect
least
hour
piperacillintazobactam
five
thousand
subject
mont
carlo
simul
perform
regimen
utilis
boselli
et
al
paramet
estim
ie
estim
clearanc
volum
etc
popul
pharmacokinet
analysi
outlin
studi
rather
boselli
studi
utilis
median
th
th
th
th
centil
piperacillin
tazobactam
concentr
plasma
elf
simul
plot
observ
piperacillin
tazobactam
concentr
plasma
elf
boselli
et
al
overlaid
simul
data
visual
inspect
made
abil
popul
pharmacokinet
model
predict
valid
data
mont
carlo
simul
perform
use
simul
mean
paramet
vector
full
covari
matrix
popul
pk
analysi
embed
subroutin
prior
program
normal
lognorm
paramet
distribut
explor
simul
abil
recapitul
origin
paramet
valu
dispers
use
select
paramet
distribut
select
piperacillin
tazobactam
median
th
percentil
thpercentil
th
percentil
total
unbound
elf
concentr
popul
identifi
everi
hour
regimen
piperacillintazobactam
gram
administ
minut
everi
hour
use
simul
unbound
plasma
elf
auc
drug
calcul
fifth
dose
hour
initi
therapi
simul
patient
perform
use
bayesian
posterior
individu
paramet
estim
ie
clearanc
volum
central
compart
intercompartment
rate
constant
regimen
piperacillintazobactam
gram
administ
minut
everi
hour
use
simul
except
patient
administ
piperacillintazobactam
gram
administ
minut
everi
hour
due
renal
impair
piperacillin
tazobactam
area
concentr
time
curv
auc
estim
plasma
unbound
plasma
fraction
total
elf
protein
bind
piperacillin
tazobactam
assum
auc
calcul
steadyst
hour
initi
therapi
patient
hour
initi
therapi
patient
egfr
correl
total
elf
unbound
plasma
exposur
piperacillin
tazobactam
assess
similarli
correl
pulmonari
permeabl
pulmonari
piperacillin
tazobactam
penetr
ratio
assess
correl
analys
use
spearman
rank
te
graphpad
prism
version
window
graphpad
softwar
san
diego
california
usa
wwwgraphpadcom
final
simul
perform
use
piperacillin
gram
administ
minut
everi
hour
fraction
simul
subject
achiev
six
predefin
pharmacodynam
target
rang
mic
mgl
determin
pharmacodynam
target
assum
relev
critic
ill
patient
unbound
plasma
elf
piperacillin
concentr
mic
dose
interv
ft
mic
dose
interv
ft
mic
trough
piperacillin
concentr
mic
ratio
cumul
respons
patient
europ
pmc
funder
author
manuscript
rang
mic
defin
suscept
piperacillin
achiev
pharmacodynam
target
estim
use
publish
mic
distribut
organ
caus
hospitalacquir
ventilatorassoci
pneumonia
refer
web
version
pubm
central
supplementari
materi
current
knowledg
topic
studi
healthi
volunt
show
piperacillin
tazobactam
exposur
lung
approxim
piperacillin
tazobactam
exposur
plasma
pauciti
data
describ
piperacillin
tazobactam
penetr
lung
critic
ill
patient
administ
standard
bolu
regimen
piperacillin
tazobactam
studi
assess
piperacillin
tazobactam
plasma
intrapulmonari
pharmacokinet
factor
influenc
pulmonari
penetr
piperacillin
tazobactam
investig
pharmacodynam
target
fraction
patient
whose
drug
concentr
mic
left
panel
middl
panel
dose
interv
fraction
patient
whose
trough
piperacillin
concentr
mic
ratio
histogram
show
mic
distribut
organ
caus
hospitalacquir
ventilatorassoci
pneumonia
tabl
piperacillin
tazobactam
popul
pharmacokinet
paramet
estim
obtain
pmetric
cl
lhr
clearanc
vc
volum
central
compart
l
k
cp
k
pc
k
celf
k
elfc
firstord
intercompartment
rate
constant
hr
central
peripher
central
elf
compart
paramet
cl
litershr
vc
liter
k
cp
hr
k
pc
hr
k
celf
hr
k
elfc
hr
v
elf
liter
